An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Trial Profile

An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Cynapsus Therapeutics; Sunovion Pharmaceuticals
  • Most Recent Events

    • 21 Mar 2018 Planned End Date changed from 31 Mar 2018 to 1 Jan 2020.
    • 21 Mar 2018 Planned primary completion date changed from 31 Mar 2018 to 1 Jan 2020.
    • 08 Jun 2017 Preliminary results (n=76) assessing safety presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top